Back to Search
Start Over
LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors.
- Source :
-
Atherosclerosis [Atherosclerosis] 1998 Jul; Vol. 139 (1), pp. 147-52. - Publication Year :
- 1998
-
Abstract
- Inflammatory processes play an important role in atherogenesis, and proinflammatory cytokines such as interleukin-1beta (IL-1beta), IL-6, and tumour necrosis factor alpha (TNFalpha) are thought to be mediators in this phenomenon. We have previously established that peritoneal macrophages of LDL-receptor knock-out mice, which are hypercholesterolemic and are prone to atherosclerosis, have an increased LPS-induced cytokine production capacity, ex vivo. The aim of the present study was to investigate whether the process leading to atherosclerosis in patients with familial hypercholesterolemia (FH) is associated with increased cytokine production capacity of peripheral blood mononuclear cells (PBMC) and/or increased expression of adhesion molecules on monocytes and lymphocytes. Furthermore, we assessed the effect of cholesterol lowering on the production capacity of PBMC, as these drugs are beneficial with regard to cardiovascular diseases. LPS-induced IL-1beta and TNFalpha production by PBMCs of 21 heterozygous FH patients appeared to be similar to the production by PBMCs of 21 healthy volunteers. In addition, expression of the LPS-receptors CD14 and beta2-integrins in nine patients and controls did not differ either. In a second series of experiments, HMG-CoA synthesis inhibitors were ineffective to change the LPS-induced production by PBMC of IL-1alpha, IL-1beta, IL-1 receptor antagonist (IL-1ra), IL-6, and TNFalpha. In conclusion, cytokine production capacity of blood cells or the expression of LPS-receptors on circulating PBMC do not deviate in subjects with FH and also do not change as a result of treatment with cholesterol synthesis inhibitors.
- Subjects :
- Animals
Anticholesteremic Agents therapeutic use
Atorvastatin
CD11 Antigens metabolism
Cohort Studies
Double-Blind Method
Heptanoic Acids therapeutic use
Heterozygote
Hyperlipoproteinemia Type II drug therapy
Lipids blood
Mice
Monocytes drug effects
Pyrroles therapeutic use
Simvastatin therapeutic use
Cytokines blood
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Hyperlipoproteinemia Type II blood
Lipopolysaccharide Receptors metabolism
Lipopolysaccharides pharmacology
Monocytes metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 0021-9150
- Volume :
- 139
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Atherosclerosis
- Publication Type :
- Academic Journal
- Accession number :
- 9699902
- Full Text :
- https://doi.org/10.1016/s0021-9150(98)00074-4